Aimei Health Technology Co Ltd 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41880 AIMEI HEALTH TECHNOLOGY CO., LTD (Exact name of registrant as specified in its charter) 10 East 53rd Street, Suite 3001New York, NY 10022(Address of principal executive offices) (Zip Code) 86-13758131392(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☒ Large accelerated filerNon-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☒No☐ As of August 13, 2026, there were 3,166,332 ordinary shares of the Company issued and outstanding. Aimei Health Technology Co., LtdForm 10-QFor the Quarterly Period Ended June 30, 2026ContentsPart IFinancial Information1Item 1Financial Statements1Unaudited Balance Sheets as of June 30, 2026 and December 31, 20251Unaudited Statements of Operations for the three and six months ended June 30, 2026 and 20252Unaudited Statements of Changes in Shareholders’ Deficit for the three and six months ended June 30, 2026 and20253Unaudited Statements of Cash Flows for the six months ended June 30, 2026 and 20254Notes to Unaudited Financial Statements5Item 2Management’s Discussion and Analysis of Financial Condition and Results of Operations17Item 3Quantitative and Qualitative Disclosures about Market Risk20Item 4Controls and Procedures20Part IIOther Information21Item 1Legal Proceedings21Item 1ARisk Factors21Item 2Unregistered Sales of Equity Securities and Use of Proceeds21Item 3Defaults Upon Senior Securities21Item 4Mine Safety Disclosures22Item 5Other Information22Item 6Exhibits22Signature23i AIMEI HEALTH TECHNOLOGY CO., LTD PART I - FINANCIAL INFORMATION AIMEI HEALTH TECHNOLOGY CO., LTDUNAUDITED BALANCE SHEETS June 30, 2026December 31, 2025 AIMEI HEALTH TECHNOLOGY CO., LTDUNAUDITED STATEMENTS OF OPERATIONS AIMEI HEALTH TECHNOLOGY CO., LTDUNAUDITED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT AIMEI HEALTH TECHNOLOGY CO., LTDUNAUDITED STATEMENTS OF CASH FLOWS AIMEI HEALTH TECHNOLOGY CO., LTDNOTES TO UNAUDITED FINANCIAL STATEMENTS NOTE 1 - ORGANIZATION AND BUSINESS BACKGROUND Aimei Health Technology Co., Ltd. (the “Company”) is a blank check company incorporated in the Cayman Islands on April 27, 2023.TheCompany was formed for the purpose of entering into a merger,share exchange,asset acquisition,share purchase,recapitalization, reorganization, or similar business combination with one or more businesses or entities. Although there is norestriction or limitation on the industry in which its target operates, the Company intends to pursue prospective targets focused onhealthcare innovation. The Company anticipates targeting what are traditionally known as “small cap” companies domiciled in NorthAmerica, Europe, and/or the Asia Pacific regions that are developing assets in the biopharmaceutical, medical technology/medicaldevice, and diagnostics space, which aligns with its management team’s experience in operating healthcare companies and in drug anddevice technology development, as well as diagnostic and other services. As of June 30, 2026, the Company had not yet commenced any operations. All activities through June 30, 2026 were related to theCompany’s formation and the Initial Public Offering (as defined below). Since the Initial Public Offering, the Company’s activity hasbeen limited to costs incurred in pursui